Amedeo Smart

Free Medical Literature Service

 

Amedeo

Neoplasms of the CNS
  Free Subscription

Articles published in
Eur J Cancer
    May 2024
  1. TRAMA A, Botta L, Stiller C, Visser O, et al
    Survival of European adolescents and young adults diagnosed with cancer in 2010-2014.
    Eur J Cancer. 2024;202:113558.
    >> Share

    April 2024
  2. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Corrigendum to "Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial" [Eur J Cancer 198 (2024) 113475].
    Eur J Cancer. 2024 Apr 23:114066. doi: 10.1016/j.ejca.2024.114066.
    >> Share

  3. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    >> Share

    March 2024
  4. PICCA A, Touat M, Belin L, Gourmelon C, et al
    REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.
    Eur J Cancer. 2024;202:114034.
    >> Share

  5. THOMAS-JOULIE A, Tran S, El Houari L, Seyve A, et al
    Prognosis of glioblastoma patients improves significantly over time interrogating historical controls.
    Eur J Cancer. 2024;202:114004.
    >> Share

  6. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Corrigendum to "Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial" [Eur J Cancer 199 (2024) 113531].
    Eur J Cancer. 2024 Mar 8:113981. doi: 10.1016/j.ejca.2024.113981.
    >> Share

    February 2024
  7. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    >> Share

  8. KOCHANEK C, Gilde C, Zimmer L, Ugurel S, et al
    Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma - An analysis of the prospective skin cancer registry ADOREG.
    Eur J Cancer. 2024;198:113508.
    >> Share

    January 2024
  9. MANDALA M, Lorigan P, Sergi MC, Benannoune N, et al
    Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
    Eur J Cancer. 2024;199:113542.
    >> Share

  10. DI GIACOMO AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, et al
    Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
    Eur J Cancer. 2024;199:113531.
    >> Share

  11. LI Z, Song Y, Farrukh Hameed NU, Yuan S, et al
    Effect of high-field iMRI guided resection in cerebral glioma surgery: A randomized clinical trial.
    Eur J Cancer. 2024;199:113528.
    >> Share

  12. HABRINGER S, Demel UM, Fietz AK, Lammer F, et al
    A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.
    Eur J Cancer. 2024;196:113436.
    >> Share

  13. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    >> Share

    December 2023
  14. LE RHUN E, Gorlia T, Felsberg J, Jongen J, et al
    Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial.
    Eur J Cancer. 2023;198:113475.
    >> Share

  15. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    >> Share

    September 2023
  16. ROSSIDES M, Mogensen H, Kampitsi CE, Talback M, et al
    Parental occupational exposure to metals and risk of cancer in the offspring: A register-based case-control study from Sweden.
    Eur J Cancer. 2023;191:113243.
    >> Share

    August 2023
  17. DOHM AE, Nakashima JY, Kalagotla H, Jiang SX, et al
    Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases.
    Eur J Cancer. 2023;192:113287.
    >> Share

  18. SOUSSAIN C, Malaise D, Choquet S, Ghesquieres H, et al
    Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral L
    Eur J Cancer. 2023;189:112909.
    >> Share

    June 2023
  19. PADOVAN M, Maccari M, Bosio A, De Toni C, et al
    Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysis.
    Eur J Cancer. 2023;191:112959.
    >> Share

  20. REIJNEVELD JC, Machingura A, Coens C, Taphoorn MJB, et al
    Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Trea
    Eur J Cancer. 2023;190:112946.
    >> Share

    May 2023
  21. DESMOULINS I, Bellio H, Mejean N, Truntzer C, et al
    Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.
    Eur J Cancer. 2023;187:161-163.
    >> Share

  22. HERTLER C, Felsberg J, Gramatzki D, Le Rhun E, et al
    Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders' Collaborative Consortium (EORTC 1419).
    Eur J Cancer. 2023 May 8:S0959-8049(23)00230-7. doi: 10.1016/j.ejca.2023.
    >> Share

    April 2023
  23. ALAFANDI A, van Garderen KA, Klein S, van der Voort SR, et al
    Association of pre-radiotherapy tumour burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status.
    Eur J Cancer. 2023;188:122-130.
    >> Share

  24. MANACORDA S, Carmena MT, Malone C, Linh Le HM, et al
    Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
    Eur J Cancer. 2023;188:98-107.
    >> Share

    March 2023
  25. CARAMANNA I, Reijneveld JC, van de Ven PM, van den Bent M, et al
    Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
    Eur J Cancer. 2023;186:38-51.
    >> Share

    December 2022
  26. CHEN PC, Yeh YM, Chu CT, Su PF, et al
    HER2 amplification in colorectal cancer with brain metastasis: A propensity score matching study.
    Eur J Cancer. 2022;181:62-69.
    >> Share

    November 2022
  27. DI GIACOMO AM, Mair MJ, Ceccarelli M, Anichini A, et al
    Immunotherapy for brain metastases and primary brain tumors.
    Eur J Cancer. 2022;179:113-120.
    >> Share

  28. TESILEANU CMS, Vallentgoed WR, French PJ, van den Bent MJ, et al
    Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.
    Eur J Cancer. 2022;175:214-223.
    >> Share

  29. TER MAAT LS, van Duin IAJ, Elias SG, van Diest PJ, et al
    Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review.
    Eur J Cancer. 2022;175:60-76.
    >> Share

  30. SERRA-BELLVER P, Versluis JM, Oberoi HK, Zhou C, et al
    Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
    Eur J Cancer. 2022;176:121-132.
    >> Share

    October 2022
  31. MUELLER T, Laternser S, Guerreiro Stucklin AS, Gerber NU, et al
    Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience.
    Eur J Cancer. 2022;178:171-179.
    >> Share

  32. WU F, Sun Y
    Re: Effect of glioma-derived immunoglobulin on biological function of glioma cells: The emerging roles of immunoglobulins in the tumor immune microenvironment.
    Eur J Cancer. 2022;178:34-36.
    >> Share

  33. LE RHUN E, Oppong FB, van den Bent M, Wick W, et al
    Thrombocytopenia limits the feasibility of salvage lomustine chemotherapy in recurrent glioblastoma: a secondary analysis of EORTC 26101.
    Eur J Cancer. 2022;178:13-22.
    >> Share

    September 2022
  34. DUTRIAUX C, Robert C, Grob JJ, Mortier L, et al
    An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases.
    Eur J Cancer. 2022;175:254-262.
    >> Share

  35. WANG Y, Lian B, Si L, Mao L, et al
    Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.
    Eur J Cancer. 2022;175:196-203.
    >> Share

  36. VOGLIS S, Schaller V, Muller T, Gonel M, et al
    Maximal surgical tumour load reduction in immune-checkpoint inhibitor naive patients with melanoma brain metastases correlates with prolonged survival.
    Eur J Cancer. 2022;175:158-168.
    >> Share

  37. TAIEB J, Svrcek M, Cohen R, Basile D, et al
    Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
    Eur J Cancer. 2022;175:136-157.
    >> Share

  38. LV J, Chen S, Chen X, Xie J, et al
    Effect of glioma-derived immunoglobulin on biological function of glioma cells.
    Eur J Cancer. 2022;175:86-98.
    >> Share

    July 2022
  39. TAN DSW, Kim SW, Ponce Aix S, Sequist LV, et al
    Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
    Eur J Cancer. 2022;172:276-286.
    >> Share

    June 2022
  40. SCHUBERT NA, Chen CY, Rodriguez A, Koster J, et al
    Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours.
    Eur J Cancer. 2022;170:196-208.
    >> Share

    May 2022
  41. CHRISTOPOULOS P, Kluck K, Kirchner M, Luders H, et al
    The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.
    Eur J Cancer. 2022;170:106-118.
    >> Share

  42. KREFT S, Glutsch V, Zaremba A, Schummer P, et al
    MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
    Eur J Cancer. 2022;167:32-41.
    >> Share

    February 2022
  43. HAGEL C, Sloman V, Mynarek M, Petrasch K, et al
    Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial.
    Eur J Cancer. 2022;164:30-38.
    >> Share

  44. KELLER KM, Krausert S, Gopisetty A, Luedtke D, et al
    Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.
    Eur J Cancer. 2022;162:107-117.
    >> Share

    January 2022
  45. BALDINI C, Younan N, Castanon Alvarez E, Ammari S, et al
    Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials.
    Eur J Cancer. 2022;163:98-107.
    >> Share

  46. SKAYEM C, Garcia G, Grill J, Aghakhani N, et al
    First case of a melanocytic intrabulbar brain tumour treated with bevacizumab.
    Eur J Cancer. 2022;162:206-208.
    >> Share

  47. STEINDL A, Brunner TJ, Heimbach K, Schweighart K, et al
    Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years.
    Eur J Cancer. 2022;162:170-181.
    >> Share

    November 2021
  48. VASSELLA E, Kashani E, Zens P, Kundig A, et al
    Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
    Eur J Cancer. 2021;159:227-236.
    >> Share

  49. SCHULPEN M, Visser O, Reedijk AMJ, Kremer LCM, et al
    Significant improvement in survival of advanced stage childhood and young adolescent cancer in the Netherlands since the 1990s.
    Eur J Cancer. 2021;157:81-93.
    >> Share

    October 2021
  50. KARSCHNIA P, Le Rhun E, Vogelbaum MA, van den Bent M, et al
    The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy.
    Eur J Cancer. 2021;156:93-108.
    >> Share

    August 2021
  51. GKEKAS I, Novotny J, Kaprio T, Beilmann-Lehtonen I, et al
    Colon cancer patients with mismatch repair deficiency are more likely to present as acute surgical cases.
    Eur J Cancer. 2021;157:1-9.
    >> Share

  52. HILBERS ML, Dimitriou F, Lau P, Bhave P, et al
    Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Eur J Cancer. 2021;156:149-163.
    >> Share

  53. LOMBARDI G, Del Bianco P, Brandes AA, Eoli M, et al
    Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
    Eur J Cancer. 2021;155:179-190.
    >> Share

    July 2021
  54. LE DU F, Dieras V, Curigliano G
    The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
    Eur J Cancer. 2021;154:175-189.
    >> Share

    May 2021
  55. CHORTI E, Kebir S, Ahmed MS, Keyvani K, et al
    Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
    Eur J Cancer. 2021;148:395-404.
    >> Share

    April 2021
  56. VERBRUGGEN LC, Kok JL, Teepen JC, Janssens GO, et al
    Clinical characteristics of subsequent histologically confirmed meningiomas in long-term childhood cancer survivors: A Dutch LATER study.
    Eur J Cancer. 2021;150:240-249.
    >> Share

  57. ZHENG MM, Tu HY, Yang JJ, Zhang XC, et al
    Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Eur J Cancer. 2021;150:23-30.
    >> Share

  58. DIMITRIOU F, Zaremba A, Allayous C, Kahler KC, et al
    Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response.
    Eur J Cancer. 2021;149:37-48.
    >> Share

  59. KARSCHNIA P, Vogelbaum MA, van den Bent M, Cahill DP, et al
    Evidence-based recommendations on categories for extent of resection in diffuse glioma.
    Eur J Cancer. 2021;149:23-33.
    >> Share

    March 2021
  60. PARTANEN M, Anghelescu DL, Hall L, Schreiber JE, et al
    Longitudinal associations between exposure to anesthesia and neurocognitive functioning in pediatric medulloblastoma.
    Eur J Cancer. 2021;148:103-111.
    >> Share

    February 2021
  61. GRAMATZKI D, Felsberg J, Hentschel B, Wolter M, et al
    Telomerase reverse transcriptase promoter mutation- and O(6)-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?
    Eur J Cancer. 2021;147:84-94.
    >> Share

  62. CLEMENT PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, et al
    Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
    Eur J Cancer. 2021;147:1-12.
    >> Share

  63. BERLANGA P, Pasqualini C, Potschger U, Sanguesa C, et al
    Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.
    Eur J Cancer. 2021;144:1-8.
    >> Share

    January 2021
  64. TOSONI A, Gatto L, Franceschi E, Di Nunno V, et al
    Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study.
    Eur J Cancer. 2021;145:171-178.
    >> Share

    December 2020
  65. CARAMANNA I, Bottomley A, Drijver AJ, Twisk J, et al
    Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
    Eur J Cancer. 2020;144:162-168.
    >> Share

    November 2020
  66. HONG AM, Waldstein C, Shivalingam B, Carlino MS, et al
    Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia.
    Eur J Cancer. 2020;142:10-17.
    >> Share

    October 2020
  67. RAUSCHENBACH L, Wieland A, Reinartz R, Kebir S, et al
    Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
    Eur J Cancer. 2020;140:130-139.
    >> Share

    September 2020
  68. MORENO L, Barone G, DuBois SG, Molenaar J, et al
    Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Eur J Cancer. 2020;136:52-68.
    >> Share

    July 2020
  69. CALLEC L, Lardy-Cleaud A, Guerrini-Rousseau L, Alapetite C, et al
    Relapsing intracranial germ cell tumours warrant retreatment.
    Eur J Cancer. 2020;136:186-194.
    >> Share

    April 2020
  70. TSAKONAS G, Lewensohn R, Botling J, Ortiz-Villalon C, et al
    An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
    Eur J Cancer. 2020;132:24-34.
    >> Share

    March 2020
  71. DELUCHE E, Antoine A, Bachelot T, Lardy-Cleaud A, et al
    Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Eur J Cancer. 2020;129:60-70.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016